, /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: ), a clinical-stage biotechnology company leveraging its proprietary DiffuSphereTM technology to optimize drug delivery for applications with significant unmet need, today announced that Eupraxia's CEO, Dr. , will present at a Tribe Public Webinar Presentation and Q&A Event titled, "Exploring The Rapid Rise of Osteoarthritis".
The event is scheduled to begin at / , July 9, 2024. To register to join the complimentary event, please visit Tribe Public at: . Once registered, participants may begin forwarding their questions for Dr.
Helliwell to Tribe Public at , or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, , will host the event and relay all questions to management. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need.
The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. DiffuSphereTM, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active phar.
